Protective effects of spironolactone against anthracycline-induced cardiomyopathy

Akpek M., Ozdogru I., Sahin O., İNANÇ M., DOĞAN A., YAZICI C., ...Daha Fazla

EUROPEAN JOURNAL OF HEART FAILURE, cilt.17, sa.1, ss.81-89, 2015 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1002/ejhf.196
  • Dergi Adı: EUROPEAN JOURNAL OF HEART FAILURE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.81-89
  • Anahtar Kelimeler: Spironolactone, Anthracycline, Cardiomyopathy, DOXORUBICIN-INDUCED CARDIOTOXICITY, METASTATIC BREAST-CANCER, OXIDATIVE STRESS, MYOCARDIAL-INFARCTION, ADRIAMYCIN CARDIOTOXICITY, CHILDHOOD-CANCER, HEART-FAILURE, UNITED-STATES, DNA-DAMAGE, ALDOSTERONE
  • Erciyes Üniversitesi Adresli: Evet

Özet

AimsThe protective effect of beta-blockers, ACE inhibitors, and ARBs on anthracycline cardiotoxicity has already been demonstrated, but the effect of aldosterone antagonism, which inhibits the last step of the renin-angiotensin-aldosterone system (RAAS), was questioned. This study sought to investigate whether spironolactone protects the heart against anthracycline-induced cardiotoxicity.